Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2018

Same author

Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.

Clinical cancer research : an official journal of the American Association for Cancer Research·2018

Same author

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Therapeutic advances in medical oncology·2018

Same author

Stress effects on FosB and interleukin-8 (<i>IL8</i>)-driven ovarian cancer growth and metastasis.

The Journal of biological chemistry·2018

Same author

Stress, inflammation, and eicosanoids: an emerging perspective.

Cancer metastasis reviews·2018

Same author

Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.

Cancer·2018

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Published on: March 25, 2015

Chitosan hydrogel for localized gene silencing.

Hee Dong Han¹, Edna M Mora, Ju Won Roh

¹Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Cancer Biology & Therapy

|March 2, 2011

Summary

This summary is machine-generated.

We developed a novel chitosan hydrogel (CH-HG) system for localized siRNA delivery, significantly inhibiting tumor growth in melanoma and breast cancer models. This local drug delivery approach enhances therapeutic efficacy for localized diseases.

More Related Videos

Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers

Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers

Published on: July 21, 2017

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Published on: April 13, 2022

Related Experiment Videos

Last Updated: Jun 4, 2026

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Chitosan/Interfering RNA Nanoparticle Mediated Gene Silencing in Disease Vector Mosquito Larvae

Published on: March 25, 2015

Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers

Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers

Published on: July 21, 2017

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Fabrication of Size-Controlled and Emulsion-Free Chitosan-Genipin Microgels for Tissue Engineering Applications

Published on: April 13, 2022

Area of Science:

Biomedical Engineering
Drug Delivery Systems
Cancer Therapy

Background:

Effective in vivo delivery of small interfering RNA (siRNA) is crucial for targeted gene silencing and therapeutic applications.
Localized drug delivery systems offer a promising strategy to enhance therapeutic efficacy and minimize systemic side effects.
Chitosan-based hydrogels are biocompatible materials with potential for controlled drug release.

Purpose of the Study:

To develop and evaluate a novel chitosan hydrogel (CH-HG) system for localized siRNA delivery in vivo.
To assess the efficacy of CH-HG mediated siRNA delivery in reducing tumor growth in preclinical cancer models.

Main Methods:

A chitosan hydrogel (CH-HG) system was prepared and loaded with siRNA.
The CH-HG system's ability to deliver siRNA into target cells in vivo was confirmed using fluorescence microscopy.
Antitumor efficacy was evaluated by intra-tumoral injection of CH-HG loaded with TG2-targeted siRNA in mouse models of melanoma (A375SM) and breast cancer (MDA-MB231).

Main Results:

The CH-HG system exhibited a temperature-dependent liquid-solid phase transition, forming a stable hydrogel in tumor tissue after intra-tumoral injection.
In vivo studies demonstrated efficient localization of Alexa555-labeled siRNA within tumor cells following CH-HG administration.
CH-HG loaded with TG2-targeted siRNA significantly inhibited tumor growth in both melanoma (72% reduction) and breast cancer (92% reduction) models compared to controls (p < 0.001).

Conclusions:

A novel local delivery method for siRNA therapy utilizing a chitosan hydrogel (CH-HG) system was successfully developed.
This CH-HG based siRNA delivery approach demonstrates significant therapeutic potential for localized diseases, including various cancer types.
The localized delivery strategy enhances siRNA targeting and efficacy while mitigating systemic risks.